Study of the Electrocardiographic Effects of TA-8995

A Phase I, Single-Centre, Randomised, Placebo and Positive- Controlled, Parallel-Group Study of the Electrocardiographic Effects of TA-8995 in Healthy Male and Female Subjects

A study in healthy males and females to see if a high single dose of TA-8995 has an effect on the ECG QTcF interval.

Inclusion Criteria:

• Healthy male or females of non-child bearing potential

Exclusion Criteria:

• Receiving any other drug therapy
• Clinically significant medical history
• Abnormal ECGs or vital signs